Tags : Myriad

MedTech

Myriad to File sPMA to the US FDA of BRACAnalysis

Shots: Myriad to seek approval based on the P-III PROfound results assessing Lynparza vs enzalutamide or abiraterone acetate in patients with metastatic castration-resistant prostate cancer who have failed prior treatment with the hormonal agent with homologous recombination repair gene mutations In 2007, Myriad & AstraZeneca entered into collaboration on Lynparza and has resulted in multiple […]Read More

Pharma

Myriad and Pfizer Signs a Service Agreement for Testing of

Shots: Myriad to provide BRACAnalysis CDx testing device in P-II study conducted to evaluate Pfizer’s talazoparib for neo-adjuvant treatment of germline BRCA-mutated triple negative breast cancer BRACAnalysis CDx is an IVD device used for qualitative detection and classification of protein coding regions & intron/exon boundaries of BRCA1 and BRCA2 gene In April, 2015 Myriad and […]Read More